zithromax and Mucositis

This RCT compared non-surgical treatment of peri-implant mucositis with or without systemic antibiotics.. Forty-eight subjects received non-surgical debridement with or without systemic Azithromax (®) (4 days), and were followed during 6 months. The checkerboard DNA-DNA hybridization method was used to analyse the microbiological material.. Five subjects were excluded due to antibiotic medication during follow-up. At baseline,1 and 3 months no group differences were found. Statistical analysis failed to demonstrate differences in probing pocket depths (PPD) values at 6 months (Mean diff PPD: 0.5 mm, SE: ±0.4 mm, 95% CI: -0.2, 1.3, p = 0.16). Mean% implant bleeding decreased between baseline and month 6 from 82.6% to 27.3% in the test, and from 80.0% to 47.5% in the control group (p < 0.02). Throughout the study, no study group differences in bacterial counts were found.. No short-term differences were found between study groups. The clinical improvements observed at 6 months may be attributed to improvements in oral hygiene. The present study does not provide evidence for the use of systemic antibiotics in treatment of peri-implant mucositis.

Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacteroides; Campylobacter; Combined Modality Therapy; Dental Implantation, Endosseous; Dental Implants; DNA, Bacterial; Fusobacterium nucleatum; Humans; Linear Models; Middle Aged; Mucositis; Peri-Implantitis; Periodontal Debridement; Periodontal Index; Single-Blind Method; Statistics, Nonparametric; Stomatitis; Treatment Outcome

Topics: Adult; Agglutination Tests; Anti-Bacterial Agents; Azithromycin; Diagnosis, Differential; Female; Humans; Infusions, Intravenous; Mucositis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Stevens-Johnson Syndrome; Stomatitis; Treatment Outcome

Topics: Azithromycin; Child; Female; Humans; Methylprednisolone; Mucositis; Mycoplasma; Pneumonia, Mycoplasma; Skin Diseases; Stevens-Johnson Syndrome; Treatment Outcome

Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Child, Preschool; Conjunctivitis; Cough; Diagnosis, Differential; Fever; Humans; Male; Mucocutaneous Lymph Node Syndrome; Mucositis; Mycoplasma pneumoniae; Stevens-Johnson Syndrome

Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Biomarkers; Child; Eyelids; Humans; Immunoglobulin M; Lip; Male; Methylprednisolone; Mucositis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma

Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Conjunctivitis; Diagnosis, Differential; Fever; Follow-Up Studies; Humans; Male; Mucositis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Treatment Outcome

In addition to the well-known signs of methotrexate toxicity, rare cutaneous side effects have been described. These cutaneous signs may provide a diagnostic clue into the diagnosis of toxicity as well as facilitate early and aggressive therapy. We describe the case of a 37-year-old male, with a diagnosis of psoriasis, who developed characteristic signs and symptoms of acute methotrexate toxicity after receiving an unknown amount of intravenous methotrexate. The patient experienced a distinct change in the morphology of his existing psoriatic plaques, which became ulcerated and necrotic in the week following the methotrexate injection. Shortly after the development of cutaneous erosions, the patient developed pancytopenia, which ultimately led to his death. Ulceration and necrosis of cutaneous psoriasis plaques may serve as a herald for the impending development of life-threatening pancytopenia in patients with acute methotrexate toxicity.

Topics: Acute Kidney Injury; Adult; Azithromycin; Biopsy; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leucovorin; Male; Methotrexate; Mucositis; Necrosis; Pancytopenia; Plasma; Psoriasis; Recombinant Proteins; Self Medication; Skin Ulcer; Trimethoprim, Sulfamethoxazole Drug Combination